MedTrace Logo

Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

NCT04858308 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 554

Last updated 2021-04-26

No results posted yet for this study

Summary

Phase 3 study to evaluate the effiacay and safety of YYC506

Conditions

  • Dyslipidemias

Interventions

DRUG

YYC506

YYC506

DRUG

Control

Active control

DRUG

YYC506 Placebo

Placebo

DRUG

Control Placebo

Placebo

Sponsors & Collaborators

  • Yooyoung Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hyo-soo Kim, Ph.D · Seoul National University Hospital

  • Hyo-soo Kim, Ph.D · Seoul National University Hospital

  • Soo Lim, Ph.D · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2021-05-31
Completion
2022-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04858308 on ClinicalTrials.gov